

# Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia

Randomised controlled trial

AIMEE SPECTOR, LENE THORGRIMSEN, BOB WOODS, LINDSAY ROYAN, STEVE DAVIES, MARGARET BUTTERWORTH and MARTIN ORRELL

**Background** A recent Cochrane review of reality orientation therapy identified the need for large, well-designed, multi-centre trials.

**Aims** To test the hypothesis that cognitive stimulation therapy (CST) for older people with dementia would benefit cognition and quality of life.

**Method** A single-blind, multi-centre, randomised controlled trial recruited 201 older people with dementia. The main outcome measures were change in cognitive function and quality of life. An intention-to-treat analysis used analysis of covariance to control for potential variability in baseline measures.

**Results** One hundred and fifteen people were randomised within centres to the intervention group and 86 to the control group. At follow-up the intervention group had significantly improved relative to the control group on the Mini-Mental State Examination ( $P=0.044$ ), the Alzheimer's Disease Assessment Scale – Cognition (ADAS–Cog) ( $P=0.014$ ) and Quality of Life – Alzheimer's Disease scales ( $P=0.028$ ). Using criteria of 4 points or more improvement on the ADAS–Cog the number needed to treat was 6 for the intervention group.

**Conclusion** The results compare favourably with trials of drugs for dementia. CST groups may have worthwhile benefits for many people with dementia.

**Declaration of interest** None. Funding detailed in Acknowledgements.

Psychological treatments for dementia, such as reality orientation, have been in use for nearly half a century (Taulbee & Folsom, 1966). Despite their longevity, their effects remain open to question and many studies have been either small, of poor methodological quality, or both (Orrell & Woods, 1996). Reality orientation operates through the presentation and repetition of orientation information, either throughout the day ('24-hour') or in groups meeting on a regular basis to engage in orientation-related activities ('classroom') (Brook *et al*, 1975). A recent Cochrane review found that reality orientation was associated with significant improvements in both cognition and behaviour, but also identified a need for large, well-designed, multi-centre trials (Spector *et al*, 1998, 2000). The results of the Cochrane review were used to develop a programme of evidence-based therapy focused on cognitive stimulation (Spector *et al*, 2001). The cognitive stimulation therapy was piloted in three care homes and one day centre, leading to improvements in cognition and depression for people participating in the programme compared with the control group (Spector *et al*, 2001). The aim of the study reported here was to evaluate the effects of cognitive stimulation therapy groups on cognition and quality of life for people with dementia, in a single-blind, multi-centre, randomised controlled trial (RCT).

## METHOD

### Participants

A total of 169 day centres and residential homes with a minimum of 15 residents each (to maximise numbers of suitable participants) were contacted in the participating areas (the National Health Service Trusts for Barking, Havering and Brentwood, Tower Hamlets, Enfield, and Camden and Islington, as well as Quantum

Care, a voluntary organisation in Hertfordshire). The researchers investigated all interested centres (day centres and residential homes) to determine whether there were adequate numbers of potential participants with dementia, by using an inclusion criteria flow chart. A minimum of eight or more eligible people were required in each centre, because five were needed for the group, leaving three or more control participants.

### Inclusion criteria

People were considered suitable for full assessment and participation if they:

- met the DSM–IV criteria for dementia (American Psychiatric Association, 1994);
- scored between 10 and 24 on the Mini-Mental State Examination (MMSE; Folstein *et al*, 1975);
- had some ability to communicate and understand communication – a score of 1 or 0 in questions 12 and 13 of the Clifton Assessment Procedures for the Elderly – Behaviour Rating Scale (CAPE–BRS; Pattie & Gilleard, 1979);
- were able to see and hear well enough to participate in the group and make use of most of the material in the programme, as determined by the researcher;
- did not have major physical illness or disability which could affect participation;
- did not have a diagnosis of a learning disability.

### Design and process of randomisation

In residential homes and day centres with at least eight suitable participants, full assessments were conducted in the week prior to, and the week following, the intervention by a researcher masked to group membership. Groups were established in 23 centres (18 residential homes and 5 day centres). Of 292 people screened, 201 participants (115 treatment, 86 control) entered the study (Fig. 1). There were more people in the intervention group because frequently centres had only eight or nine suitable participants, and five of these had to be randomised to the intervention group. Control group participants from each centre continued with usual activities while the group therapy was in progress. For most residential homes 'usual activities'

consisted of doing nothing. For the other centres, usual activities included games such as bingo, music and singing, arts and crafts, and activity groups. Within each centre, one researcher (the therapist) ran the group and the other (the assessor) conducted initial and follow-up assessments, ensuring masking. Participants were randomly allocated into treatment and control groups. The assessor ordered the names of the selected participants for each centre alphabetically and allocated numbers in sequence according to the total number to be randomised (8–10). The therapist independently placed identical numbered discs into a sealed container and the first five numbers to be drawn out formed the treatment group. The appropriate multi-centre and local research ethics committees granted ethical approval. Informed consent was obtained from participants. After an explanation of the study, those who agreed to participate were asked to sign the consent form in the presence of a witness (usually a member of staff). People whom the staff felt were too impaired to understand the nature of the study were excluded, and it usually followed that they were too impaired to participate in the groups. Using the results from our pilot study, we estimated that a sample size of 64 in each group was required to achieve 80% power to detect a difference in means of 2 points (MMSE). This assumed that the common standard deviation was 4.0, using a two-group *t*-test with a 0.05 (two-sided) significance level.

### The programme

The 14-session programme ran twice a week for 45 min per session over 7 weeks. It was designed using the theoretical

concepts of reality orientation and cognitive stimulation. It largely focused on a trial of cognitive stimulation (Breuil *et al*, 1994), which was identified through the systematic reviews as having the most significant results. Topics included using money, word games, the present day and famous faces. The programme included a ‘reality orientation board’, displaying both personal and orientation information, including the group name (chosen by participants). The board was to provide a focus, reminding people of the name and nature of the group, and creating continuity. Each session began with a warm-up activity, typically a soft-ball game. This was a gentle, non-cognitive exercise, aiming to provide continuity and orientation by beginning all sessions in the same way. Sessions focusing on themes (such as childhood and food) allowed the natural process of reminiscence but had an additional focus on the current day. Multi-sensory stimulation was introduced when possible. Sessions encouraged the use of information processing rather than factual knowledge. For example, in the ‘faces’ activity, people were asked, ‘Who looks the youngest?’ ‘What do these people have in common?’, with factual information as an optional extra. A range of activities for each session enabled the facilitator to adapt the level of difficulty of the activities to take into account the group’s cognitive capabilities, interests and gender mix. The 14-session programme has been previously described in depth (Spector *et al*, 2001).

### Assessment measures

#### Cognition

The primary outcome variable was the MMSE (Folstein *et al*, 1975). This is a brief,

widely used test of cognitive function, with good reliability and validity. The secondary outcome variable was the Alzheimer’s Disease Assessment Scale – Cognition (ADAS–Cog; Rosen *et al*, 1984); this is a more sensitive scale measuring cognitive function and including more items that assess short-term memory. It is frequently used in drug trials as the principal cognitive measure, allowing the effects of cognitive stimulation therapy to be compared with antedementia drugs.

#### Quality of life

The Quality of Life – Alzheimer’s Disease scale (QoL–AD; Logsdon *et al*, 1999) was used as a secondary outcome variable; it has 13 items covering the domains of physical health, energy, mood, living situation, memory, family, marriage, friends, chores, fun, money, self, and life as a whole. This brief, self-report questionnaire has good internal consistency, validity and reliability (Thorgrimsen *et al*, 2003).

#### Communication

The Holden Communication Scale (Holden & Woods, 1995), which is completed by staff, covers a range of social behaviour and communication variables, including conversation, awareness, pleasure, humour and responsiveness.

#### Behaviour

The Clifton Assessment Procedures for the Elderly – Behaviour Rating Scale (CAPE–BRS; Pattie & Gilleard, 1979) covers general behaviour, personal care and behaviour towards others. It has good reliability and validity, and was included to assess the overall level of functional impairment and dependency.

#### Global functioning

The Clinical Dementia Rating scale (CDR; Hughes *et al*, 1982), completed by the researcher, provided a global rating of dementia severity at baseline.

#### Depression

The Cornell Scale for Depression in Dementia (Alexopoulos *et al*, 1988) rates depression in five broad categories (mood-related signs, behavioural disturbance, physical signs, biological functions and ideational disturbance) using information from interviews with staff and participants. Good reliability and validity have been demonstrated.




Fig. 1 Profile of trial and attrition. MMSE, Mini-Mental State Examination.

**Table 1** Characteristics and scores of participants at baseline assessment

Characteristics	Treatment group (n=115)	Control group (n=86)	All (n=201)
Age (years): mean (s.d.)	85.7 (6.2)	84.7 (7.9)	85.3 (7.0)
Female:male ratio <sup>1</sup>	4.0:1 (96, 24)	3.3:1 (62, 19)	3.7:1 (158, 43)
MMSE score: mean (s.d.)	14.2 (3.9)	14.8 (3.8)	14.4 (3.8)
ADAS-Cog score: mean (s.d.)	27.4 (7.2)	26.8 (7.9)	27.0 (7.5)
CDR score: mean (s.d.)	1.4 (0.5)	1.4 (0.5)	1.4 (0.5)
QoL-AD score: mean (s.d.)	33.2 (5.9)	33.3 (5.7)	33.3 (5.8)
Cornell score: mean (s.d.)	5.2 (5.0)	6.9 (4.7)	5.5 (4.9)
RAID score: mean (s.d.)	8.4 (8.0)	10.1 (8.5)	9.1 (8.2)
CAPE-BRS score: mean (s.d.)	11.3 (4.7)	11.5 (5.1)	11.4 (4.8)
Holden score: mean (s.d.)	11.1 (5.9)	9.9 (5.5)	10.6 (5.7)

ADAS-Cog, Alzheimer's Disease Assessment Scale - Cognition; CAPE-BRS, Clifton Assessment Procedures for the Elderly - Behaviour Rating Scale; CDR, Clinical Dementia Rating; Cornell, Cornell Scale for Depression in Dementia; Holden, Holden Communication Scale; MMSE, Mini-Mental State Examination; QoL-AD, Quality of Life - Alzheimer's Disease; RAID, Rating Anxiety in Dementia.

1. Actual *n* in parentheses.

### Anxiety

Anxiety was assessed using the scale Rating Anxiety in Dementia (RAID; Shankar *et al.*, 1999); this rates anxiety in four main categories (worry, apprehension and vigilance, motor tension, and automatic hypersensitivity) using interviews with staff and participants. It has good validity and reliability.

### Analysis

Data were entered into the Statistical Package for the Social Sciences, version 10 for Windows (SPSS, 2001). An intention-to-treat analysis was conducted and analysis

of covariance (ANCOVA) was chosen as the method of analysis because it controls for variability in pre-test scores (the 'covariate'; Vickers & Altman, 2001). Age, gender and baseline score on the scale being examined were entered as covariates, together with 'centre' entered as a random factor, because treatment was defined as participation in the group programme within the confines of one of the 23 centres.

### RESULTS

Of the 115 participants in the treatment group 97 were assessed at follow-up, as

were 70 of the 86 control participants (Fig. 1). The mean attendance was 11.6 sessions (s.d.=3.2, range 2-14) and 89% of people attended seven or more sessions. Table 1 compares treatment and control participants' characteristics in terms of age, gender and baseline scores and provides information about the total participant group. We attempted to collect data on years of education but in the vast majority of instances this was not available. None of the participants had been prescribed an acetylcholinesterase inhibitor.

### Difference between groups at follow-up

In Table 2, significance levels set at 5% are presented from the ANCOVA comparing groups (treatment and control) in all instances. Significant results for covariates (centre and/or gender) are included when they occurred. At follow-up, the treatment group had significantly higher scores on MMSE and ADAS-Cog and rated their quality of life (QoL-AD) more positively than the control group did, and the confidence intervals for the differences between groups were above zero for all three measures. There was a trend towards an improvement in communication in the treatment group ( $P=0.09$ ) but no difference between the groups in terms of functional ability (CAPE-BRS), anxiety or depression. Centre emerged as a significant covariate in relation to ADAS-Cog, Holden Communication Scale, Cornell and RAID scales,

**Table 2** Change from baseline in measures of efficacy at follow-up: intention-to-treat analysis

Efficacy measure <sup>1</sup>	Change from baseline		Group difference		ANCOVA: between-group difference	ANCOVA: other significant differences <sup>1</sup>
	Treatment Mean (s.d.)	Control Mean (s.d.)	Mean (s.e.)	95% CI		
MMSE	+0.9 (3.5)	-0.4 (3.5)	+1.14 (0.09)	0.57 to 2.27	$F=4.14, P=0.044$	None
ADAS-Cog	+1.9 (6.2) <sup>3</sup>	-0.3 (5.5) <sup>4</sup>	+2.37 (0.87)	0.64 to 4.09	$F=6.18, P=0.014$	C: $P=0.006$
QoL-AD	+1.3 (5.1)	-0.8 (5.6)	+1.64 (0.78)	0.09 to 3.18	$F=4.95, P=0.028$	G: $P=0.010$
Holden	+0.2 (6.1)	-3.2 (6.3)	+2.3 (0.93)	-0.45 to 4.15	$F=2.92, P=0.090$	C: $P=0.009$ G: $P=0.001$
CAPE-BRS	-0.2 (6.1)	-0.7 (5.5)	+0.40 (0.65)	-0.9 to 1.69	$F=0.58, P=0.449$	C: $P<0.001$ G: $P=0.001$
RAID	-0.5 (10.2)	-0.7 (10.3)	-1.30 (1.10)	-3.48 to 0.87	$P=0.200$	C: $P<0.001$
Cornell	0 (6.2)	-0.5 (7.0)	+0.12 (0.72)	-1.56 to 1.31	$P=0.648$	C: $P<0.001$

ADAS-Cog, Alzheimer's Disease Assessment Scale - Cognition; ANCOVA, analysis of covariance; CAPE-BRS, Clifton Assessment Procedures for the Elderly - Behaviour Rating Scale; Cornell, Cornell Scale for Depression in Dementia; Holden, Holden Communication Scale; QoL-AD, Quality of Life - Alzheimer's Disease; RAID, Rating Anxiety in Dementia.

1. Primary outcome measure: MMSE; secondary outcome measures: ADAS-Cog and QoL-AD.

2. C, difference between centres; G, difference between genders.

3. Zero or more points improvement:  $n=58$  (50%); 4 or more points improvement:  $n=34$  (30%).

4. Zero or more points improvement:  $n=32$  (37%); 4 or more points improvement:  $n=11$  (13%).

**Table 3** Numbers needed to treat: comparison of cognitive stimulation therapy with antidementia drug trials

Treatment	Analysis 1 <sup>1</sup> NNT (95% CI)	Analysis 2 <sup>1</sup> NNT (95% CI)
CST programme	8 (4–144)	6 (4–17)
Rivastigmine, 6–12 mg (Corey-Bloom <i>et al</i> , 1998; Rösler <i>et al</i> , 1999)	4 (3–6)	13 (7–11)
Donepezil, 5 mg	5 (4–9)	10 (5–180)
Donepezil, 10 mg (Rogers <i>et al</i> , 1998)	5 (3–8)	4 (3–7)
Galantamine, 32 mg (Wilcock <i>et al</i> , 2000)	5 (4–8)	6 (4–9)
Tacrine, <sup>2</sup> 160 mg (Knapp <i>et al</i> , 1994)		7 (3–10)

CST, cognitive stimulation therapy; NNT, number needed to treat.

1. Analysis 1 – Alzheimer's Disease Assessment Scale – Cognition score with no deterioration as improvement; analysis 2 – same score with increase of 4 or more as improvement.

2. Tacrine is not licensed for use in the UK.

and CAPE–BRS score. A number of gender differences emerged. Quality of life for women in the treatment group improved more than that for the men, whereas the quality of life for men in the control group deteriorated significantly more than it did for the women. Dependency levels (CAPE–BRS) and communication (Holden) also deteriorated for men in the treatment group (though less than for the men in the control group). In contrast, women in the treatment group improved on both measures whereas women in the control group deteriorated (though less than the men in the control group).

### Numbers needed to treat

The number needed to treat (NNT) is a calculation of the number of people who needed to be treated in a particular intervention in order to achieve one favourable outcome. It is calculated as the reciprocal of the 'absolute risk reduction': the difference in the proportion experiencing a specified adverse outcome between the control and treatment groups. Using the formulae and framework provided in a previous study (Livingston & Katona, 2000) including acetylcholinesterase inhibitors, two NNT analyses using the ADAS–Cog scores were performed in this study (Table 3):

(a) when calculating no deterioration (score  $\geq 0$ ) as improvement and any deterioration ( $< 0$ ) as adverse, 50% of the treatment group improved compared with 37% of the control group: thus eight people needed to be

treated in order for one to benefit (95% CI 4–144);

(b) when calculating an increase in score of 4 or over as improvement and 3 or below as adverse, 30% of the treatment group improved compared with 13% of the control group: thus six people needed to be treated in order for one to benefit (95% CI 4–17).

## DISCUSSION

### Major findings

This evidence-based programme of cognitive stimulation therapy showed significant improvements in two measures of cognition, including the MMSE (the primary outcome measure), and also in the QoL–AD (a secondary outcome measure). The improvements in cognition are consistent with the findings of earlier studies (Woods, 1979; Breuil *et al*, 1994). The overall ADAS–Cog (a secondary outcome measure) change indicated improvement in a number of factors. With the exception of explicit rehearsal in place orientation, which is directly questioned, there was no obvious reason why participation in groups should have had a direct practice effect on any other tasks in the ADAS–Cog, such as word recall or recognition. This suggests that generalised cognitive benefits resulted from inclusion in the programme. Nevertheless, such groups probably need to be ongoing, at least weekly, to increase the chance of the relative benefits being sustained.

Contrary to the Cochrane review (Spector *et al*, 1998) we found no change

in behaviour in this study (and the former review found only one individual trial that demonstrated a significant difference in behaviour (Baines *et al*, 1987)). Changes in cognition might be unlikely to have any impact on areas of functional dependence described in the CAPE–BRS, such as feeding and dressing (Woods, 1996). Other authors (Zanetti *et al*, 1995) have suggested that behavioural outcome measures are often not sensitive enough to detect the functional impact of cognitive stimulation programmes. There were positive trends in communication, which had not been shown empirically in any of the earlier reality orientation trials. Communication is a factor that is likely to deteriorate in individuals moving into residential care, yet the small-group context was probably novel for many of the participants, perhaps exercising long unused communication skills. It is not known why women reacted more favourably to the programme. For men, being in the minority in most groups could have created discomfort and a reluctance to communicate.

### Variation between centres

There was a significant variation between centres from baseline to follow-up in measures of cognition (ADAS–Cog), behaviour, mood and communication. Some centres appeared more institutionalised, and in these there were poor staff–patient relationships and functioning was not optimised. Thus, it might have been the case that the effects of groups were not strong enough to combat the effects of a negative environment. Moreover, in some centres with a better quality of social environment, perhaps including a local programme of activities, residents might have been functioning near their optimum, leaving little scope for improvement. Groups including people at different stages of dementia were sometimes difficult to run. People with milder dementia could become irritated by people with more severe cognitive impairment, and observing their confusion might have been off-putting and hence detrimental to the group process. Pitching the sessions at an appropriate level was clearly important. It is possible that the social interaction provided by the groups could have been of benefit, but our Cochrane review (Spector *et al*, 1998) found that in RCTs social groups appeared to be of no benefit to cognition.

## Limitations

Rigorous inclusion criteria were necessary to ensure a reasonably homogeneous participant group, and were aimed at recruiting people who were able to participate and less likely to leave the study. This meant many centres were excluded because of insufficient numbers. Cluster randomisation might have been useful in allowing centres with five to seven suitable candidates to be included, but would have had the disadvantage that large numbers of clusters would be needed to ensure statistical power and external validity (Bowling, 1997). More importantly, the significant difference between centres on many scales in this study shows that it would have been difficult to ensure the comparability of clusters. Outside the context of a research trial, groups would probably be selected through clinical judgement, considering how people would mix; and people with poorer vision or hearing, or with greater communication difficulties, might be included to make up numbers.

There were a number of other limitations. In the randomisation procedure ideally the generation of the allocation sequence, enrolment into the trial and allocation to group should be separate and performed by different, independent staff. Differences in control conditions between centres meant that the 'control group' was not homogeneous; however, 'usual activities' generally meant doing nothing. Last, in contrast to the results on the primary and secondary outcome measures which were rated directly with the participants, none of the scales rated by staff (e.g. mood, communication, behaviour) showed significant improvements for the cognitive stimulation therapy group. Staff perceptions about the therapy groups might have introduced a bias into the ratings of the scales. We took precautions to avoid this by ensuring that the local member of staff who acted as co-therapist was not involved in completion of the rating scales. However, it is likely that other staff could have been aware of which people were in the groups and this might have influenced their ratings.

## Comparison with acetylcholinesterase inhibitors

Number-needed-to-treat analyses were previously performed for three acetylcholinesterase inhibitors: tacrine, rivastigmine and donepezil (Livingston & Katona, 2000). Analyses were performed identically

in this study, considering two levels of change as improvement, so that a direct comparison could be made (Table 3). Calculations were also included for galantamine, using the results from another trial (Wilcock *et al*, 2000). These comparisons show that for small improvements or no deterioration, the programme was not quite as effective as rivastigmine, donepezil and galantamine. For greater improvements (4 or more points), cognitive stimulation therapy did as well as galantamine or tacrine and substantially better than rivastigmine or the lower dosage of donepezil (5 mg). Only the higher dosage of donepezil (10 mg) had a smaller NNT. These results are particularly interesting considering that the drug programmes lasted for 24 weeks, 26 weeks or 30 weeks compared with only 7 weeks of cognitive stimulation therapy. However, since these drug studies applied only to Alzheimer's disease, and since drug therapy and psychological therapy are different forms of treatment, some caution is required when interpreting these comparisons.

## Mechanisms for change

There are a number of possible mechanisms of change. The learning environment during sessions was designed to be optimal for people with dementia, for example by focusing on implicit memory and integrating reminiscence and multi-sensory stimulation throughout the programme. Stimulation in the group could improve cognition and might make participants feel more able to communicate. The groups could work against the excess disability due to the 'malignant social psychology' of a negative social environment (Kitwood, 1997) by improving self-esteem through social stimulation and encouragement. Finally, groups positively reinforced questioning, thinking and interacting with other people, objects and the environment. This effect might have extended beyond the groups, with people communicating more effectively and responding to the environment and to others.

Recent research has highlighted strategies that can involve memory training and cognitive stimulation programmes. Providing participants with 'didactic training' (forming mental images of words) and 'problem solving' (practical steps to manage daily problems, such as using notebooks and calendars) has been shown to result in small but short-lived changes in

memory performance (Zarit *et al*, 1982). The use of external memory aids, such as diaries, calendars, large clocks and clear signposting, is becoming increasingly common for people with dementia. Research is also identifying ways of creating an optimal learning environment: for example, 'errorless learning' involves encouraging people, when learning new information, only to respond when they are sure that they are correct, thus avoiding interference effects; and 'spaced retrieval' involves learning and retaining information by recalling information over increasingly long periods (Clare & Woods, 2001).

## Implications

This study found improvements in both the primary (MMSE) and secondary (ADAS-Cog and QoL-AD) outcome measures for people in the cognitive stimulation therapy group. Although there is a body of research on the various psychological interventions for dementia, much of it lacks methodological rigour and might not be considered 'evidence-based'. The previous RCTs were small, with the largest having 56 participants (Breuil *et al*, 1994), and could be criticised for weaknesses such as lack of standardisation of groups, selection and detection biases, and absence of intention-to-treat analyses. Our study is the only major evidence-based trial examining the effectiveness of cognitive stimulation therapy for dementia. Some guidelines counsel against the use of cognitive stimulation programmes because of the possibility of adverse reactions such as frustration (American Psychiatric Association, 1997). This study has shown that cognitive improvements are associated with benefits to quality of life rather than deterioration. Indeed, this is the first study to show improvements in quality of life of people with dementia participating in such a programme. The findings suggest that reality orientation groups, which are widely used both throughout the UK and internationally, are likely to be beneficial for many people with dementia and should be regarded more positively by staff, carers and service providers. Future research needs to identify the most effective ways of teaching care staff to implement this programme, the possible benefits of a longer-term cognitive stimulation therapy programme, and the potential effects of combining cognitive stimulation therapy with drug therapy.

## ACKNOWLEDGEMENTS

This paper is dedicated to the memory of Margaret Butterworth, who died in December 2002 having worked tirelessly for the needs of carers and people with dementia over many years. The work was led by Dr Martin Orrell, who received funding from the NHS London Regional Office, Research and Development Programme, and Barking, Havering and Brentwood Community NHS Trusts. The views expressed in the publication are those of the authors and not necessarily those of the NHS or the Department of Health. We thank all the residents and staff of the residential homes and day centres who participated in the study. We also thank Professor Stephen Senn, and Pasco Fearon for statistical advice.

## REFERENCES

- Alexopoulos, G. S., Abrams, P. C., Young, R. C., et al (1988)** Cornell Scale for depression in dementia. *Biological Psychiatry*, **23**, 271–284.
- American Psychiatric Association (1994)** *Diagnostic and Statistical Manual of Mental Disorders* (4th edn) (DSM-IV). Washington, DC: APA.
- (1997) Practice guidelines for the treatment of Alzheimer's disease and other dementias of late life. *American Journal of Psychiatry*, **154** (suppl), 1–39.
- Baines, S., Saxby, P. & Ehler, K. (1987)** Reality orientation and reminiscence therapy. A controlled cross-over study of elderly confused people. *British Journal of Psychiatry*, **151**, 222–231.
- Bowling, A. (1997)** *Research Methods in Health: Investigating Health and Health Services*. Milton Keynes: Open University Press.
- Breuil, V., De Rotrou, J., Forette, F., et al (1994)** Cognitive stimulation of patients with dementia: preliminary results. *International Journal of Geriatric Psychiatry*, **9**, 211–217.
- Brook, P., Degun, G. & Maher, M. (1975)** Reality orientation, a therapy for psychogeriatric patients: a controlled study. *British Journal of Psychiatry*, **127**, 42–45.
- Clare, L. & Woods, R. T. (2001)** *Cognitive Rehabilitation in Dementia*. Hove: Psychology Press.
- Corey-Bloom, J., Anand, R. & Veach, J. (1998)** A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate) in patients with mild to moderately severe Alzheimer's disease. ENA 713 B352 Study Group. *International Journal of Geriatric Psychopharmacology*, **1**, 55–65.
- Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975)** Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, **12**, 189–198.
- Holden, U. P. & Woods, R. T. (1995)** *Positive Approaches to Dementia Care* (3rd edn). Edinburgh: Churchill Livingstone.
- Hughes, C. P., Berg, L., Danziger, W. L., et al (1982)** A new clinical scale for the staging of dementia. *British Journal of Psychiatry*, **140**, 566–572.
- Kitwood, T. (1997)** *Dementia Reconsidered*. Milton Keynes: Open University Press.
- Knapp, M. J., Knopman, D. S., Soloman, P. R., et al (1994)** A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. *JAMA*, **271**, 985–991.

## CLINICAL IMPLICATIONS

- Cognitive stimulation therapy groups appear to improve both cognitive function and quality of life for people with dementia.
  - The degree of benefit for cognitive function appears similar to that attributable to acetylcholinesterase inhibitors.
  - The groups were popular with the participants, and can be conducted in a variety of settings.
- ## LIMITATIONS
- To maintain the benefits relative to the control group, it is likely that cognitive stimulation therapy would need to be continued on a regular basis long after the end of the 14-session programme.
  - Staff ratings might have included an element of bias despite efforts to reduce this.
  - Many centres were excluded because they had insufficient numbers or residents fitting the inclusion criteria.

AIMEE SPECTOR, PhD, LENE THORGRIMSEN, BA, Department of Psychiatry and Behavioural Sciences, University College London; BOB WOODS, MSc, Dementia Services Development Centre, University of Wales, Bangor; LINDSAY ROYAN, BA, Department of Clinical Psychology, Petersfield Centre, Harold Hill, London; STEVE DAVIES, MSc, Department of Psychology, Derwent Unit, Princess Alexandra Hospital, Harlow, Essex; MARGARET BUTTERWORTH (deceased), BA, MARTIN ORRELL, PhD, Department of Psychiatry and Behavioural Sciences, University College London, UK

Correspondence: Dr Martin Orrell, Department of Psychiatry and Behavioural Sciences, UCL, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK. Tel: 020 7679 9452; fax: 020 7679 9426; e-mail: m.orrell@ucl.ac.uk

(First received 13 January 2003, final revision 13 May 2003, accepted 13 May 2003)

**Livingston, G. & Katona, C. (2000)** How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. *International Journal of Geriatric Psychiatry*, **15**, 203–207.

**Logsdon, R., Gibbons, L. E., McCurry, S. M., et al (1999)** Quality of life in Alzheimer's disease: patient and caregiver reports. *Journal of Mental Health and Aging*, **5**, 21–32.

**Orrell, M. & Woods, B. (1996)** Tacrine and psychological therapies in dementia – no contest? Editorial comment. *International Journal of Geriatric Psychiatry*, **11**, 189–192.

**Pattie, A. H. & Gilleard, C. J. (1979)** *Clifton Assessment Procedures for the Elderly (CAPE)*. Sevenoaks: Hodder & Stoughton.

**Rogers, S. L., Farlow, M. R., Doody, R. S., et al (1998)** A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. *Neurology*, **50**, 136–145.

**Rosen, W. G., Mohs, R. C. & Davis, K. L. (1984)** A new rating scale for Alzheimer's disease. *American Journal of Psychiatry*, **141**, 1356–1364.

**Rösler, M., Amand, R., Cicin-Sain, A., et al (1999)** Efficacy and safety of rivastigmine in patients with

Alzheimer's disease: international randomised controlled trial. *BMJ*, **318**, 633–638.

**Shankar, K., Walker, M., Frost, D., et al (1999)** The development of a valid and reliable scale for anxiety in dementia. *Aging and Mental Health*, **3**, 39–49.

**Spector, A., Orrell, M., Davies, S., et al (1998)** Reality orientation for dementia: a review of the evidence for its effectiveness. *Cochrane Library*, issue 4. Oxford: Update Software.

—, —, —, et al (2000) Reality orientation for dementia: a systematic review of the evidence of effectiveness from randomised controlled trials. *Gerontologist*, **40**, 206–212.

—, —, —, et al (2001) Can reality orientation be rehabilitated? Development and piloting of an evidence-based programme of cognition-based therapies for people with dementia. *Neuropsychological Rehabilitation*, **11**, 377–397.

**SPSS (2001)** *SPSS for Windows, Version 10*. Chicago, IL: SPSS.

**Taulbee, L. R. & Folsom, J. C. (1966)** Reality orientation for geriatric patients. *Hospital and Community Psychiatry*, **17**, 133–135.

**Thorgirnsen, L., Selwood, A., Spector, A., et al (2003)** Whose quality of life is it anyway? The validity and reliability of the Quality of Life – Alzheimer's Disease (QOL-AD) scale. *Alzheimer's Disease and Associated Disorders*, in press.

**Vickers, A. J. & Altman, D. G. (2001)** Analysing controlled trials with baseline and follow up measurements. *BMJ*, **323**, 1123–1124.

**Wilcock, G. K., Lilienfeld, S. & Gaens, E. (2000)** Efficacy and safety of galantamine in patients with mild to

moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International Study Group. *BMJ*, **321**, 1445–1449.

**Woods, R. T. (1979)** Reality orientation and staff attention: a controlled study. *British Journal of Psychiatry*, **134**, 502–507.

— (1996) Psychological 'therapies' in dementia. *Handbook of the Clinical Psychology of Ageing* (ed. R. T. Woods), pp. 575–600. Chichester: John Wiley & Sons.

**Zanetti, O., Frisoni, G. B., De Leo, D., et al (1995)** Reality orientation therapy in Alzheimer's disease: useful or not? A controlled study. *Alzheimer's Disease and Associated Disorders*, **9**, 132–138.

**Zarit, S. H., Zarit, J. M. & Reever, K. E. (1982)** Memory training for severe memory loss: effects on senile dementia patients and their families. *Gerontologist*, **22**, 373–377.